NEWS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Immune Design to Present at Jefferies 2017 London Healthcare Conference
SEATTLE and SOUTH SAN FRANCISCO, Calif., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on cancer, today announced that Carlos Paya, M.D., Ph.D., President and Chief Executive Officer, will present at the Jefferies 2017 London
View HTML
Toggle Summary Immune Design Announces Multiple Presentations at CTOS and SITC Highlighting the Breadth of Existing & Future Product Candidates
SEATTLE and SOUTH SAN FRANCISCO, Calif., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on oncology, today announced seven presentations at the upcoming Connective Tissue Oncology Society (CTOS) and the Society for Immunotherapy of
View HTML
Toggle Summary Immune Design Reports Third Quarter 2017 Financial Results and Provides Corporate Update
Company conference call at 1:30 p.m. PT today
View HTML
Toggle Summary Immune Design to Report Third Quarter 2017 Financial Results & Provide Corporate Update
SEATTLE and SOUTH SAN FRANCISCO, Calif., Oct. 27, 2017 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on cancer, today announced that it will report third quarter 2017 financial results and provide a corporate update after the close of U.S.
View HTML
Toggle Summary Immune Design Prices $80.0 Million Public Offering of Common Stock
SEATTLE and SOUTH SAN FRANCISCO, Calif., Oct. 24, 2017 (GLOBE NEWSWIRE) -- Immune Design Corp. (Nasdaq:IMDZ) announced today the pricing of an underwritten public offering of 19,500,000 shares of its common stock at a price to the public of $4.10 per share.
View HTML
Toggle Summary Immune Design Announces Proposed Public Offering of Common Stock
SEATTLE and SOUTH SAN FRANCISCO, Calif., Oct. 23, 2017 (GLOBE NEWSWIRE) -- Immune Design Corp. (Nasdaq:IMDZ) announced today that it plans to offer and sell up to 16,000,000 shares of its common stock in an underwritten public offering. All of the shares in the proposed offering are to be sold by
View HTML
Toggle Summary Immune Design Announces G100's Receipt of Orphan Drug Designation by the EMA for the Treatment of Follicular Non-Hodgkin's Lymphoma
SEATTLE and SOUTH SAN FRANCISCO, Calif., Oct. 19, 2017 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on oncology, today announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation for G100, Immune Design's investigational
View HTML
Toggle Summary Immune Design Announces Positive FDA Feedback on Phase 3 Clinical Trial Design for CMB305 in Synovial Sarcoma Patients
CMB305 Monotherapy vs. Placebo in the Maintenance Setting PFS Analysis for Potential Full Approval as Early as 24 Months After Study Start Conference Call and Webcast Tomorrow at 5:30am PT/8:30am ET SEATTLE and SOUTH SAN FRANCISCO, Calif., Oct. 16, 2017 (GLOBE NEWSWIRE) -- Immune Design
View HTML
Toggle Summary Immune Design Announces Four Upcoming Presentations at the SITC 32nd Annual Meeting
SEATTLE and SOUTH SAN FRANCISCO, Calif., Sept. 25, 2017 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on oncology, today announced that four abstracts have been accepted for presentation at the Society for Immunotherapy of Cancer (SITC) 32 nd Annual
View HTML
Toggle Summary New Randomized Data From CMB305 + Checkpoint Inhibitor Study Demonstrate Greater Clinical Benefit and Immune Response
Phase 2 Interim Analysis Data Presented at ESMO 2017 Congress SEATTLE and SOUTH SAN FRANCISCO, Calif., Sept. 08, 2017 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on oncology, today announced that an interim analysis of its ongoing, randomized
View HTML